Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 123-134

  Eberhardt, Wilfried E E ^a   Mitchell, Paul ^b   Schiller, Joan H ^c   Brown, Michael P ^d   Thomas, Michael ^e   Mills, Glenn ^f   Jehl, Valentine ^g   Urva, Shweta R ^g   De Leo, Jeffrey J ^g   Gogov, Sven ^g   Papadimitrakopoulou, Vassiliki ^h  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b AUSTIN HOSPITAL   (Australia)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dose limiting toxicity; Everolimus; Non small cell lung cancer

Indexed keywords

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SIROLIMUS; TREATMENT OUTCOME;

EID: 84899126795     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9958-3     Document Type: Article

References (30)

1. National Comprehensive Cancer Network (2011) Nccn clinical practice guidelines in oncology: non-small cell lung cancer, Version 2.2012
2. Ramalingam S, Ab S (2006) Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 11:655-665 (Pubitemid 43967620)
3. Behera M, Tk O, Chen Z, Sa K, Fr K, Cp B, Ss R (2012) Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung Cancer 77:331-338
4. Ma B, Pj H (2004) The tor pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348
5. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'reilly T, Natt F, Hall J, Ha L, Thomas G (2005) The Mtor inhibitor Rad001 sensitizes tumor cells to Dna-damaged induced apoptosis through inhibition Of P21 translation. Cell 120:747-759 (Pubitemid 40568794)
6. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'reilly T, Stolz B, Marti A, Thomas G, Ha L (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative Rad001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261 (Pubitemid 38114106)
7. Mabuchi S, Da A, Dc C, Klein-Szanto A, Litwin S, Mk H, Hensley H, Tc H, Jr T (2007) Rad001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67:2408-2413 (Pubitemid 46548923)
8. La Monica S, Galetti M, Rr A, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D, Pg P (2009) Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78:460-468
9. Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A (2010) The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through C-Met inhibition. Mol Cancer Res 8:1142-1151
10. Cx X, Li Y, Yue P, Tk O, Ss R, Fr K, Sy S (2011) The combination of Rad001 and Nvp-Bez235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One 6, E20899
11. Afinitor (Everolimus) Tablets For Oral Administration [Prescribing Information] (2012) East Hanover, Nj, Usa: Novartis Pharmaceuticals Corporation
12. Afinitor Summary Of Product Characteristics (2012) West Sussex, United Kingdom: Novartis Europharm Limited
13. Votubia Summary Of Product Characteristics (2012) West Sussex, United Kingdom: Novartis Europharm Limited
14. Baselga J, Campone M, Piccart M, Ha B, Hs R, Sahmoud T, Noguchi S, Gnant M, Ki P, Lebrun F, Jt B, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Gn H (2012) Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med 366:520-529
15. Ss R, Rd H, Saba N, Tk O, Kauh J, Dm S, Sy S, Strychor S, Tighiouart M, Egorin Mj FH, Fr K (2010) Phase 1 and pharmacokinetic study of Everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 116:3903-3909
16. O'reilly T, Pm M, Wartmann M, Lassota P, Brandt R, Ha L (2011) Evaluation of the Mtor inhibitor, Everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 22:58-78
17. Sandler A, Gray R, Mc P, Brahmer J, Schiller J, Dowlati A, Lilenbaum R, Johnson D (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
18. Goldstraw P, Crowley J, Chansky K, Dj G, Pa G, Rami-Porta R, Pe P, Rusch V, Sobin L (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706-714 (Pubitemid 47357522)
19. Mg K, Pj H, Mr S, Feyer P, Clark-Snow R, Jm K, Gr M, Lw C, Mj C, Rj G, Sm G (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947 (Pubitemid 46630595)
20. Herrstedt J, Ms A, Roila F, Vv K (2005) ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (Nv). Ann Oncol 16(Suppl 1):I77-I79 (Pubitemid 40872999)
21. Therasse P, Sg A, Ea E, Wanders J, Rs K, Rubinstein L, Verweij J, Van Glabbeke M, At VO, Mc C, Sg G (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
22. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Fj R, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Ha L, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610
23. O'donnell A, Faivre S, Ha B, Iii RD, Papadimitrakopoulou V, Shand N, Ha L, Hazell K, Zoellner U, Jm K, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595
24. Xu B, Wu Y, Shen L, Ye D, Jappe A, Cherfi A, Wang H, Yuan R (2011) Two dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematol Oncol 4:3
25. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K (2010) Phase I clinical and pharmacokinetic study of Rad001 (Everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40:17-23
26. Dt M, Gj R, Cg A, Je G, Rt H, Mg K, Lm K, Pao W, Pizzo B, Na R, Va M (2007) Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110:599-605 (Pubitemid 47106149)
27. Vansteenkiste J, Solomon B, Boyer M, Wolf J, Miller N, Sl D, Pylvaenaeinen I, Petrovic K, Dimitrijevic S, Anrys B, Laack E (2011) Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. J Thorac Oncol 6:2120-2129
28. Al H, Ej S, Vk W, Sun J, Cj R, Am L, Fong L, Dr B, Je R (2011) A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 117:4194-4200
29. Ke B, Wp P, Younis I, He U, Ma M, Gc B, Sy Z, Jp G, Jj L, Truax R, Kl M, La H, Mm O'n, Broadwater G, Hi H, Jc B (2011) A Phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (Bee). Cancer Chemother Pharmacol 67:465-474
30. Jc Y, Shah M, Ito T, Cl B, Em W, Van Cutsem E, Tj H, Okusaka T, Capdevila J, Eg DV, Tomassetti P, Me P, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523